181 related articles for article (PubMed ID: 11078020)
1. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
Sluis-Cremer N; Arion D; Parniak MA
Cell Mol Life Sci; 2000 Sep; 57(10):1408-22. PubMed ID: 11078020
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
3. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs).
Yoshida Y; Honma M; Kimura Y; Abe H
ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979
[TBL] [Abstract][Full Text] [Related]
4. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.
Isel C; Ehresmann C; Walter P; Ehresmann B; Marquet R
J Biol Chem; 2001 Dec; 276(52):48725-32. PubMed ID: 11668180
[TBL] [Abstract][Full Text] [Related]
5. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.
Álvarez M; Nevot M; Mendieta J; Martínez MA; Menéndez-Arias L
J Biol Chem; 2018 Feb; 293(7):2247-2259. PubMed ID: 29275329
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.
von Kleist M; Metzner P; Marquet R; Schütte C
PLoS Comput Biol; 2012 Jan; 8(1):e1002359. PubMed ID: 22275860
[TBL] [Abstract][Full Text] [Related]
8. The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.
Boyer PL; Vu BC; Ambrose Z; Julias JG; Warnecke S; Liao C; Meier C; Marquez VE; Hughes SH
J Med Chem; 2009 Sep; 52(17):5356-64. PubMed ID: 19678643
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
Menéndez-Arias L
Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
11. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
Bertoletti N; Chan AH; Schinazi RF; Anderson KS
Molecules; 2020 Oct; 25(20):. PubMed ID: 33096918
[TBL] [Abstract][Full Text] [Related]
12. Genetic mechanisms of resistance to NRTI and NNRTI.
Soriano V; de Mendoza C
HIV Clin Trials; 2002; 3(3):237-48. PubMed ID: 12032883
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
14. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
16. Understanding the molecular mechanism of drug resistance of anti-HIV nucleosides by molecular modeling.
Chong Y; Chu CK
Front Biosci; 2004 Jan; 9():164-86. PubMed ID: 14766357
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants and molecular mechanisms for the resistance of HIV-1 RT to nucleoside analogues.
Deval J; Courcambeck J; Selmi B; Boretto J; Canard B
Curr Drug Metab; 2004 Aug; 5(4):305-16. PubMed ID: 15320702
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM; Tanuma J; Oka S; Singh K; Kodama EN; Sarafianos SG
J Biol Chem; 2012 Aug; 287(35):29988-99. PubMed ID: 22761416
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
Das K; Arnold E
Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.
Meteer JD; Schinazi RF; Mellors JW; Sluis-Cremer N
Antiviral Res; 2014 Jan; 101():62-7. PubMed ID: 24211331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
